Figure 1. Identification of immunogenic long peptides encompassing both TH1 and cytotoxic T lymphocyte epitopes. To select candidate CDCA1- and KIF20A-derived long peptides (LPs) that would encompass both TH1 and cytotoxic T lymphocyte (CTL) epitopes, we combined the software-assisted prediction of HLA class II-binding peptides with known HLA-A2 or HLA-A24-restricted short CTL epitopes (SPs). Peripheral blood mononuclear cells (PBMCs) derived from healthy donors and cancer patients were used to investigate the immunogenicity as well as the in vitro cross-priming potential of these LPs. HLA-A2 or -A24 transgenic mice were employed to confirm the cross-priming potential of CDCA1- and KIF20A-derived LPs in vivo. LPs similar to those that we identified might allow for the propagation of both TH1 and CTL responses in the course of cancer immunotherapy. IFNγ, interferon γ; IL-2, interleukin-2.